To receive future news releases direct to your inbox, subscribe by emailing

Historical news and financial information can also be found at under the Company’s profile.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
Resverlogix Closes $13.5 Million Private Placement
Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences
Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders
Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
Resverlogix Announces $26 Million Private Placement
Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich
Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Resverlogix Intends to Pursue U.S. Listing
Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer’s Disease (CTAD) Asia and Alzheimer’s Association International Conference (AAIC)
Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
Resverlogix Announces Withdrawal of Public Offering of Units
Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the “Shock and Kill” Approach
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
Resverlogix Announces Lifting by TSX of Review
Resverlogix Closes US$30 Million Loan
Resverlogix Advances US$30 Million Loan Closing Documentation
Resverlogix Announces Proposed Offering of Units
Resverlogix Announces TSX Review Update
Resverlogix Announces US$30 Million Loan Commitment Letter
Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial
Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Resverlogix Highlights Key Accomplishments and 2018 Targets
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement